Cargando…

Expression and clinical significance of CMTM1 in hepatocellular carcinoma

BACKGROUND: CKLF Like Marvel Transmembrane Domain Containing 1 (CMTM1) plays a role in breast cancer and lung cancer, but studies on the occurrence and development of CMTM1 in hepatocellular carcinoma (HCC) have not been reported. METHODS: The Cancer Genome Atlas (TCGA) database and immunohistochemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xin, Zhang, Shidong, Tian, Run, Zheng, Chuanjun, Xu, Yuge, Wang, Tianxian, Bei, Chunhua, Zhang, Huixia, He, Xiao, Zhu, Xiaonian, Tan, Shengkui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862999/ https://www.ncbi.nlm.nih.gov/pubmed/33585698 http://dx.doi.org/10.1515/med-2021-0221

Ejemplares similares

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Zhang, Shidong, et al.
Publicado: (2020)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma
por: Zheng, Chuanjun, et al.
Publicado: (2022)

Correlations between chromobox homolog 8 and key factors of epithelial–mesenchymal transition in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2019)

Retraction Note to: Correlations between chromobox homolog 8 and key factors of epithelial–mesenchymal transition in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Single Nucleotide Polymorphisms of CBX4 and CBX7 Decrease the Risk of Hepatocellular Carcinoma
por: Tan, Chao, et al.
Publicado: (2019)

Expression and clinical significance of PcG-associated protein RYBP in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2017)

Overexpression and clinical significance of MYC-associated zinc finger protein in pancreatic carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2016)

Single nucleotide polymorphisms in MLH1 predict poor prognosis of hepatocellular carcinoma in a Chinese population
por: Zhu, Xiaonian, et al.
Publicado: (2017)

MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transition
por: Luo, Wei, et al.
Publicado: (2016)

hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration
por: Tan, Shengkui, et al.
Publicado: (2022)

High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
por: Muranushi, Ryo, et al.
Publicado: (2021)

CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma
por: Huang, Yue, et al.
Publicado: (2022)

Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2016)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Polymorphisms in MicroRNA Target Sites of Forkhead Box O Genes Are Associated with Hepatocellular Carcinoma
por: Tan, Chao, et al.
Publicado: (2015)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells
por: Huang, Xiaoting, et al.
Publicado: (2021)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells
por: Li, Wujun, et al.
Publicado: (2017)

Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
por: Chui, Noreen Nog‐Qin, et al.
Publicado: (2021)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling
por: Xu, Gang, et al.
Publicado: (2017)

Migrasomes and tetraspanins in hepatocellular carcinoma: current status and future prospects
por: Zhang, Zhongqi, et al.
Publicado: (2023)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
por: Chen, Zhi, et al.
Publicado: (2021)

Up‐regulation of miR‐10b‐3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5
por: Guan, Lianyue, et al.
Publicado: (2018)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
por: Wang, Hanfeng, et al.
Publicado: (2022)

CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
por: Chen, Zhao-Hui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k2v61p6gqh4gl9epmutgp8gfti